Maintenance Notice

Due to necessary scheduled maintenance, the JMIR Publications website will be unavailable from Monday, December 24 through Wednesday, December 26 inclusive. We apologize in advance for any inconvenience this may cause you.

Who will be affected?

Advertisement

Citing this Article

Right click to copy or hit: ctrl+c (cmd+c on mac)

Published on 01.09.17 in Vol 6, No 9 (2017): September

This paper is in the following e-collection/theme issue:

    Protocol

    Legacy Effect of Delayed Blood Pressure-Lowering Pharmacotherapy in Middle-Aged Individuals Stratified by Absolute Cardiovascular Disease Risk: Protocol for a Systematic Review

    1Menzies Institute for Medical Research, University of Tasmania, Hobart, TAS, Australia

    2Centre for Research in Evidence-Based Practice, Bond University, Gold Coast, QLD, Australia

    3School of Public Health, Curtin University, Perth, WA, Australia

    4Centre of Cardiovascular Research & Education in Therapeutics, School of Public Health and Preventive Medicine, Monash University, Melbourne, VIC, Australia

    Corresponding Author:

    Chau Le Bao Ho, MD

    Menzies Institute for Medical Research

    University of Tasmania

    Private Bag 23

    Hobart, TAS, 7001

    Australia

    Phone: 61 406656898

    Fax:61 0362267764

    Email:


    ABSTRACT

    Background: Many national and international guidelines recommend that the initiation of blood pressure (BP)-lowering drug treatment for the primary prevention of cardiovascular disease (CVD) should no longer be based on BP level alone, but on absolute cardiovascular risk. While BP-lowering drug treatment is beneficial in high-risk individuals at any level of elevated BP, clinicians are concerned about legacy effects on patients with low-to-moderate risk and mildly elevated BP who remain “untreated”.

    Objective: We aim to investigate the legacy effect of delayed BP-lowering pharmacotherapy in middle-aged individuals (45-65 years) with mildly elevated BP (systolic BP 140-159 mmHg and/or diastolic BP 90-99 mmHg) stratified by absolute risk for primary prevention of CVD, but particularly in the low-risk (<10% five-year absolute risk) group.

    Methods: Randomized trials of BP-lowering therapy versus placebo or pretreated subjects in active comparator studies with posttrial follow-up will be identified using a 2-step process. First, randomized trials of BP-lowering therapy will be identified by (1) retrieving the references of trials included in published systematic reviews of BP-lowering therapy, (2) retrieving studies published by the Blood Pressure Lowering Treatment Trialists’ Collaboration (BPLTTC), and (3) checking studies referenced in the 1993 World Health Organization/International Society of Hypertension meeting memorandum on BP management. Posttrial follow-up studies will then be identified by forward citation searching the randomized trials identified in step 1 through Web of Science. The search will include randomized controlled trials with at least 1-year in-trial period and a posttrial follow-up phase. Age is the major determinant of absolute cardiovascular risk, so the participants in our review will be restricted to middle-aged adults who are more likely to have a lower cardiovascular risk profile. The primary outcome will be all-cause mortality. Secondary outcomes will include cardiovascular mortality, fatal stroke, fatal myocardial infarction, and death due to heart failure.

    Results: The searches for existing systematic reviews and BPLTTC studies were piloted and modified. The study is expected to be completed before June 2018.

    Conclusions: The findings of this study will contribute to the body of knowledge concerning the beneficial, neutral, or harmful effects of delayed BP-lowering drug treatment on the primary prevention of CVD in patients with mildly elevated BP and low-to-moderate CVD risk.

    Trial Registration: PROSPERO International Prospective Register of Systematic Reviews: CRD42017058414; https://www.crd.york.ac.uk/PROSPERO/display_record.asp?ID=CRD42017058414 (Archived by WebCite® at http://www.webcitation.org/6t6sa8O2Q)

    JMIR Res Protoc 2017;6(9):e177

    doi:10.2196/resprot.8362

    KEYWORDS

    Crowdfunding campaign to support this specific research

    We help JMIR researchers to raise funds to pursue their research and development aimed at tackling important health and technology challenges. If you would like to show your support for this author, please donate using the button below. The funds raised will directly benefit the corresponding author of this article (minus 8% admin fees). Your donations will help this author to continue publishing open access papers in JMIR journals. Donations of over $100 may also be acknowledged in future publications.

    keyboard with crowdfunding key instead of enter key

    Suggested contribution levels: $20/$50/$100



    Introduction

    Despite improvements in the management of cardiovascular disease (CVD) over the past five decades, it remains the leading cause of death and disability in the world [1]. CVD was responsible for approximately 17.5 million deaths worldwide in 2012 [1]. In updated guidelines for the primary prevention of CVD from Australasia [2,3], the United Kingdom [4], and Europe [5], blood pressure (BP)-lowering pharmacotherapy is indicated by absolute CVD risk, not BP level alone. In contrast, the US guideline (the Eighth Joint National Committee) [6] is still heavily focused on BP level and age, despite the fact that BP-lowering therapy is beneficial for the reduction of CVD mortality and morbidity at sufficiently high CVD absolute risk, regardless of the level of BP elevation [7]. The use of BP-lowering drug treatment in high-risk settings has achieved consensus in Australasian [2,3], European [5], and the US guidelines [6]. In low-risk individuals, BP-lowering drugs are not recommended by guidelines in Australia [2], New Zealand [3] or the United Kingdom [4], unless BP exceeds a level of 160/100 mmHg, whereas the European [5] and US [6] guidelines recommended an early initiation at a BP level of 140/90 mmHg. However, both approaches raised many concerns from clinicians and a gap still exists between guidelines and clinical practice [8].

    An international expert consultation was recently performed to solve the controversy of whether adults with grade 1 hypertension (<140/90 mmHg) and low-to-moderate CVD risk should be treated by drug therapy [9]. Morales-Salinas et al [9] recommended an early initiation of BP-lowering pharmacotherapy primarily from the results of the Heart Outcomes Prevention Evaluation (HOPE-3) trial [10] and a meta-analysis by Thomopoulos et al [11] for adults with grade 1 hypertension and moderate CVD risk; however, the two studies were likely to include a number of high-risk participants. In the HOPE-3 trial [10], participants with an INTERHEART risk score higher than 16 (a value of 16 or higher indicates a high CVD risk) accounted for 32.5% of the total sample [12]. In the meta-analysis by Thomopoulos et al [11], the CVD risk was calculated by CVD death rate in the control group, while the CVD risk score used in most guidelines is for fatal and nonfatal CVD events. Thus, the benefits of BP-lowering pharmacotherapy in low-to-moderate-risk individuals remain unclear, as opposed to the benefits achieved by treating high risk individuals. Most clinicians use BP-lowering pharmacotherapy based on BP criteria alone, due to the perceived potential risk of irreversible target organ damage (the “legacy effect”) for delayed therapy [5]. Studies that would help us to answer this question include those that have extended follow-up in the posttrial period. Such studies include the Systolic Hypertension in the Elderly Program trial [13] of approximately 22 years, the Hypertension Detection and Follow-Up Program [14] of 8.3 years, and the second Australian National Blood Pressure study [15] of 10.6 years. Participants in these studies are still likely to be at high baseline risk of CVD due to the advanced age and diabetic status in the inclusion criteria of the trials [13-15]. Hence, the concern of legacy effects on low-to-moderate-risk individuals has not been addressed. Age is the most important determinant of adverse cardiovascular risk, so the participants in our review are restricted to middle-aged adults who are more likely to have a broader cardiovascular risk profile. Therefore, in this systematic review and meta-analysis, we will investigate the effects of BP-lowering drug treatments in middle-aged individuals with mildly elevated BP, stratified by absolute CVD risk.


    Methods

    Review Objectives

    Aim 1

    We will conduct a systematic review and meta-analysis of published and unpublished studies of randomized placebo control trials with a posttrial follow-up phase that included middle-aged participants without overt CVD, and examine these studies for CVD mortality and all-cause mortality.

    Aim 2

    We will conduct a subgroup analysis (where possible) of participants in these trials classified as low-, moderate-, and high-absolute CVD risk by the Framingham Risk Score (FRS) used in the Australia guideline [2], or the risk calculator used by the Blood Pressure Lowering Treatment Trialists’ Collaboration (BPLTTC) [16] which uses routine clinical information if information on cholesterol levels is not available for fatal and nonfatal CVD events and all-cause mortality. We will conduct an individual patient data meta-analysis, if data are available.

    Primary Null Hypothesis

    There will be no significant difference in CVD mortality or all-cause mortality between patients who have drug therapy initiated earlier (active treatment arm) versus delayed or not initiated (control arm) in individuals at low-absolute CVD risk.

    Secondary Hypotheses

    Hypothesis 1

    There will be no significant difference in CVD mortality or all-cause mortality between patients who have drug therapy initiated earlier (active treatment arm) versus delayed or not initiated (control arm) in individuals at moderate-absolute CVD risk.

    Hypothesis 2

    There will be no significant difference in CVD mortality or all-cause mortality between patients who have drug therapy initiated earlier (active treatment arm) versus delayed or not initiated (control arm) in individuals at high-absolute CVD risk.

    Hypothesis 3

    In-trial CVD events (fatal and nonfatal) will be incremental by risk classification estimated by FRS or equivalent risk calculated at baseline.

    Criteria for Considering Studies in the Review

    Population

    The study will include men and nonpregnant women from 45 to 65 years of age. At least 80% of participants from each trial must have had mildly elevated BP at baseline, defined as a systolic BP of 140- 159 mmHg and/or diastolic BP 90- 99 mmHg. Furthermore, all included participants must not have exhibited any history of CVD at baseline: myocardial infarction, angina pectoris, coronary bypass surgery, coronary angioplasty, stroke, transient ischaemic attack, carotid endarterectomy, surgery for peripheral vascular disease, intermittent claudication or renal failure (creatinine >1.5 times the upper limit of normal). If trials included participants different than those of interest (eg, secondary prevention, moderately-elevated or highly-elevated BP), we will attempt to access individual patient data and subsequently select participants that meet specific criteria.

    Intervention

    The study will focus on all types of BP-lowering drugs, except for some types that have limited clinical use due to the risk of side effects and availability (eg, ganglion blockers, reserpine, rauwolfia).

    Comparison

    The study will compare the effects of BP-lowering drug treatments in active treatment groups versus control treatment groups. However, if comparative trials with two active comparators had an extended posttrial follow-up phase and individual data are available, we will perform a legacy effect analysis per Nelson et al [15]. We will reclassify participants into previous treatment (early treatment) groups and treatment naïve (delayed treatment) groups. The previous treatment group will include participants who were on BP-lowering drug treatments at trial registration and then went on a specific drug withdrawal program. The treatment naïve group will include those who were not on any treatments at trial registration.

    Outcomes

    Primary outcomes will include all-cause mortality in both randomization and follow-up periods. Secondary outcomes will include CVD mortality (defined as deaths due to stroke, myocardial infarction, and heart failure), fatal stroke, fatal myocardial infarction, and fatal heart failure. Nonfatal CVD events will be included if the measurements of outcomes are similar between trials. Vital status in posttrial periods must be assessed by national death databases or equivalent records.

    Study Design

    Randomized controlled trials with at least 1-year in-trial period and a posttrial follow-up phase.

    Language

    No restriction (English and non-English studies).

    Publication Type

    Published and unpublished studies reported in peer-reviewed journals, reports, conference abstracts, and theses.

    Search Methods for Identification of Studies

    Randomized trials of BP-lowering therapies versus placebo or active comparator with posttrial follow-up periods will be identified using a 2-step process. First, randomized trials of BP-lowering therapy will be identified by (1) retrieving the references of trials included in published systematic reviews of BP-lowering therapy, (2) retrieving studies published by the BPLTTC, and (3) checking studies referenced in the 1993 WHO/ISH (World Health Organization/International Society of Hypertension) meeting memorandum on BP management [17]. To identify existing systematic reviews, we will search Medline Ovid using a combination of Medical Subject Headings and text word terms for BP-lowering regimes and high BP with a systematic review filter (see Multimedia Appendix 1). Web of Science will be used to retrieve the references of studies cited by the systematic reviews, and these will be exported to an Endnote file. To identify studies from the BPLTTC, a text word search in the title, abstract, and author fields will be conducted in Ovid Medline and the retrieved references will be exported to the Endnote file. Web of Science will be used to retrieve the references of studies cited in the WHO/ISH meeting memorandum and these will be exported to the Endnote file. After removing duplications, the Endnote file will be screened to identify randomized trials of BP-lowering therapies versus placebo or active comparators. In the second step of the search, posttrial follow-up studies will be identified by forward citation searching the randomized trials identified in step 1. Web of Science will be used for forward citation searches of each of the original trials, with the citations exported to another Endnote file. After the removal of duplications in the Endnote file, the file will be searched using terms related to extended follow-up (see Multimedia Appendix 2). The resulting titles and abstracts will be screened independently by two reviewers using the review eligibility criteria.

    Study Selection

    First, two independent reviewers will screen a small sample of papers found in the search to revise any unclear or inappropriate inclusion criteria. In the full selection process, two reviewers will independently scan the results of the search and determine the eligibility of the studies. In the initial screening of titles and abstracts, the studies will be included if they meet the inclusion criteria or they do not have enough information for exclusion. Rejected citations will be recorded and classified as irrelevant studies. All potentially relevant articles will be screened through full text for a final decision. If a paper does not have sufficient information to assess eligibility, we will attempt to contact the authors; the paper will be classified as a potentially relevant article and checked in sensitivity analyses if authors do not reply after one month. If we identify trials that meet our inclusion criteria but lack data on the posttrial follow-up period, we will run a forward citation search from those studies. If a study has multiple citations, we will report separate citations but analyze these reports as a single study. We will also liaise with the BPLTTC for any individual patient data from trials meeting our inclusion criteria.

    Data Extraction and Quality Assessment

    Data extraction forms (detailed in Textbox 1) and quality assessment forms will be piloted on a small group of studies. Two reviewers will independently perform data extraction and quality assessment in the prespecified form. If any disagreements arise, the reviewers will discuss consensus or consult with the third reviewer. A report of correction or amendments to the prespecified form will be recorded.


    Textbox 1. Information required for data extraction.
    View this box

    Quality Assessment

    The risk of bias will be assessed by two reviewers following the Cochrane Risk of bias tool [18] which includes the following criteria: random sequence generation (selection bias); allocation concealment (selection bias); blinding of participants, personnel, and outcome (performance and detection bias); and incomplete outcome data (attrition bias). The bias will be assessed as unclear, low-risk, or high-risk. Publication bias will be judged by observing the asymmetry of funnel plots; if they are asymmetric, contour-enhanced funnel plots will then be analyzed to examine whether publication bias alone caused the asymmetry. We will also use Egger’s meta-regression model to assess the relationship between the observed effect sizes and the size of studies [19].

    Data Synthesis and Analysis

    After pooling all eligible studies, we will design a fixed-effect model and assess the heterogeneity by visually inspecting the forest plots, Chi-squared tests, and I2tests. Statistical heterogeneity will be recorded when the studies’ confidence intervals exhibit poor overlap, the P-value of the test of heterogeneity is 0.1 or lower, or the I2value is 0.5 or greater. In these cases, we will also perform an analysis using a random-effects model. All trial endpoints will be treated as dichotomous variables and grouped by time from randomization. In the fixed-effect model, the Mantel-Haenszel method model will be used to combine risk ratios of each outcome [20]. We will conduct a subgroup analysis in which available risk calculators will be used to stratify participants by the baseline absolute CVD risk for fatal and nonfatal CVD events. In a sensitivity analysis, each study will be removed (one at a time) to assess the impact of each study on the pooled outcomes. The Cochrane software (Revman) [21] will be used for meta-analysis, selective reporting, and other sources of bias.

    Ethics and Dissemination

    This systematic review will analyze nonidentifiable data; thus, a formal ethics approval is unlikely to be crucial. The study protocol was registered with the International Prospective Register of Systematic Review (PROSPERO) with the reference number CRD42017058414. The current study will contribute a chapter of a PhD thesis (CH).


    Results

    We are currently in the process of developing the search strategy. The search in Medline via Ovid has been piloted and modified. The analysis is expected to complete before June 2018.


    Discussion

    Given the strong beliefs held by many clinicians that early treatment of elevated BP is necessary to prevent CVD events, it is not possible to conduct a randomized controlled trial of early versus late treatment at present. This is particularly true for patients with mildly elevated BP and low CVD risk, as studies would require a large sample size of participants or a long follow-up period because approximately 10% of CVD events are expected to occur within 10 years. In addition, clinicians are questioning the real benefits, adverse effects, and medical costs of the life-long intervention of BP-lowering drug treatment. The findings of this study will contribute to the body of knowledge concerning the beneficial, neutral, or harmful effects of delayed BP-lowering drug treatment in patients with mildly elevated BP and low-to-moderate CVD risk.

    Limitations

    Due to the changes in definitions of CVD and diagnostic methods used over time, we predict that it will be difficult to combine these outcomes in a meta-analysis. This issue inherently generates bias in selection, detection, attrition, and reporting.

    Acknowledgments

    CLBH is a PhD candidate at Menzies Institute for Medical Research, and has received a PhD scholarship from Merle Weaver Postgraduate Scholarship. JD is supported by National Health and Medical Research Council Screening and Test Evaluation Program Grant 633003. CR is supported by a National Health and Medical Research Council Senior Research Fellowship (1045862).

    Conflicts of Interest

    MRN has served on an advisory board for AMGEN in the last 5 years. All other authors declare no conflicts of interest.

    Multimedia Appendix 1

    Search strategy developed for Medline via Ovid to identify existing systematics review.

    PDF File (Adobe PDF File), 22KB

    Multimedia Appendix 2

    Search terms related to extended follow-up.

    PDF File (Adobe PDF File), 19KB

    References

    1. World Health Organization. Fact sheet - Cardiovascular disease (CVDs). 2016.   URL: http://www.who.int/mediacentre/factsheets/fs317/en/ [accessed 2017-03-22] [WebCite Cache]
    2. National Vascular Disease Prevention Alliance. Guidelines for the management of absolute cardiovascular disease risk. 2012.   URL: http://www.cvdcheck.org.au/index.php?option=com_content&view=article&id=47&Itemid=27 [accessed 2017-08-27] [WebCite Cache]
    3. New Zealand Guidelines Group. The assessment and management of cardiovascular risk. Wellington, New Zealand; 2003.   URL: https://www.health.govt.nz/system/files/documents/publications/cvd_risk_full.pdf [accessed 2017-08-27] [WebCite Cache]
    4. National Clinical Guideline Centre UK. Hypertension: the clinical management of primary hypertension in adults: update of clinical guidelines 18 and 34. National Institute for Health and Clinical Excellence: Guidance 2011 Aug. [Medline]
    5. Mancia G, Fagard R, Narkiewicz K, Redon J, Zanchetti A, Böhm M, Task Force for the Management of Arterial Hypertension of the European Society of Hypertension and the European Society of Cardiology. 2013 ESH/ESC practice guidelines for the management of arterial hypertension. Blood Press 2014 Feb;23(1):3-16. [CrossRef] [Medline]
    6. James P, Oparil S, Carter B, Cushman WC, Dennison-Himmelfarb C, Handler J, et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA 2014 Feb 05;311(5):507-520. [CrossRef] [Medline]
    7. Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ 2009 May 19;338:b1665 [FREE Full text] [Medline]
    8. Jansen J, Bonner C, McKinn S, Irwig L, Glasziou P, Doust J, et al. General practitioners' use of absolute risk versus individual risk factors in cardiovascular disease prevention: an experimental study. BMJ Open 2014 May 15;4(5):e004812 [FREE Full text] [CrossRef] [Medline]
    9. Morales SA, Coca A, Olsen M, Sanchez RA, Sebba-Barroso WK, Kones R, et al. Clinical perspective on antihypertensive drug treatment in adults with grade 1 hypertension and low-to-moderate cardiovascular risk: an international expert consultation. Curr Probl Cardiol 2017 Jul;42(7):198-225. [CrossRef] [Medline]
    10. Lonn EM, Bosch J, López-Jaramillo P, Zhu J, Liu L, Pais P, HOPE-3 Investigators. Blood-pressure lowering in intermediate-risk persons without cardiovascular disease. N Engl J Med 2016 May 26;374(21):2009-2020. [CrossRef] [Medline]
    11. Thomopoulos C, Parati G, Zanchetti A. Effects of blood pressure lowering on outcome incidence in hypertension: 2. Effects at different baseline and achieved blood pressure levels--overview and meta-analyses of randomized trials. J Hypertens 2014 Dec;32(12):2296-2304. [CrossRef] [Medline]
    12. McGorrian C, Yusuf S, Islam S, Jung H, Rangarajan S, Avezum A, INTERHEART Investigators. Estimating modifiable coronary heart disease risk in multiple regions of the world: the INTERHEART Modifiable Risk Score. Eur Heart J 2011 Mar;32(5):581-589. [CrossRef] [Medline]
    13. Kostis JB, Cabrera J, Cheng JQ, Cosgrove NM, Deng Y, Pressel SL, et al. Association between chlorthalidone treatment of systolic hypertension and long-term survival. JAMA 2011 Dec 21;306(23):2588-2593. [CrossRef] [Medline]
    14. Hypertension Detection and Follow-up Program Cooperative Group. Persistence of reduction in blood pressure and mortality of participants in the Hypertension Detection and Follow-up Program. JAMA 1988 Apr 08;259(14):2113-2122. [Medline]
    15. Nelson M, Chowdhury E, Doust J, Reid C, Wing L. Ten-year legacy effects of baseline blood pressure 'treatment naivety' in the Second Australian National Blood Pressure study. J Hypertens 2015 Nov;33(11):2331-2337. [CrossRef] [Medline]
    16. Blood Pressure Lowering Treatment Trialists' Collaboration, Sundström J, Arima H, Woodward M, Jackson R, Karmali K, et al. Blood pressure-lowering treatment based on cardiovascular risk: a meta-analysis of individual patient data. Lancet 2014 Aug 16;384(9943):591-598. [CrossRef] [Medline]
    17. Zanchetti A, Chalmers JP, Arakawa K, Gyarfas I, Hamet P, Hansson L, et al. The 1993 guidelines for the management of mild hypertension: memorandum from a WHO/ISH meeting. Blood Press 1993 Jun;2(2):86-100. [Medline]
    18. Higgins J, Altman D, Gøtzsche PC, Jüni P, Moher D, Oxman AD, Cochrane Bias Methods Group, Cochrane Statistical Methods Group. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ 2011 Oct 18;343:d5928 [FREE Full text] [Medline]
    19. Chaimani A, Mavridis D, Salanti G. A hands-on practical tutorial on performing meta-analysis with Stata. Evid Based Ment Health 2014 Nov;17(4):111-116. [CrossRef] [Medline]
    20. Mantel N, Haenzel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 1959 Apr;22(4):719-748. [Medline]
    21. The Cochrane Collaboration. Review Manager (RevMan). Copenhagen: The Nordic Cochrane Centre; 2014. [Computer program]. Version 5.3   URL: http://community.cochrane.org/tools/review-production-tools/revman-5/about-revman-5 [accessed 2017-08-29] [WebCite Cache]


    Abbreviations

    BP: blood pressure
    BPLTTC: Blood Pressure Lowering Treatment Trialists’ Collaboration
    CVD: cardiovascular disease
    FRS: Framingham Risk Score
    HOPE-3: Heart Outcomes Prevention Evaluation trial
    WHO/ISH: World Health Organization/International Society of Hypertension


    Edited by G Eysenbach; submitted 06.07.17; peer-reviewed by P Sever; comments to author 15.07.17; revised version received 20.07.17; accepted 21.07.17; published 01.09.17

    ©Chau Le Bao Ho, Sharon Sanders, Jenny Doust, Monique Breslin, Christopher M Reid, Mark Raymond Nelson. Originally published in JMIR Research Protocols (http://www.researchprotocols.org), 01.09.2017.

    This is an open-access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work, first published in JMIR Research Protocols, is properly cited. The complete bibliographic information, a link to the original publication on http://www.researchprotocols.org, as well as this copyright and license information must be included.